The African-PREDICT Study

Summary

The African-PREDICT study aims to (i) generate new knowledge on the early pathophysiology accompanying hypertension development in black South Africans; and (ii) to identify early novel markers or predictors for the development of hypertension and cardiovascular outcome. By employing also in Africa the latest cutting-edge scientific technologies to measure single and multiple biomarkers proven to predict hypertension and cardiovascular outcome (such as multiplex analyses, proteomics and metabolomics), precision medicine may have the potential to lead to novel strategies in preventing and treating hypertension in Africa.

Conditions

• Cardiovascular Diseases
• Hypertension
• Health Risk Behaviors
• Arterial Stiffness
• Young
• Renin Hypertension

Sponsors & Collaborators

• Medical Research Council, South Africa

  collaborator OTHER

• National Research Foundation of South Africa

  collaborator OTHER

• GlaxoSmithKline

  collaborator INDUSTRY

• Medical Research Council

  collaborator OTHER_GOV

• Pfizer

  collaborator INDUSTRY

• Boehringer Ingelheim

  collaborator INDUSTRY

• Novartis

  collaborator INDUSTRY

• Mediclinic Hospital

  collaborator UNKNOWN

• Roche Diagnostics GmbH

  collaborator INDUSTRY

• North-West University, South Africa

  lead OTHER

Principal Investigators

• Alta Schutte, PhD · University of New South Wales

• Carina MC Mels, PhD · North-West University

Eligibility

Min Age

20 Years

Max Age

30 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2013-02-04

Primary Completion

2017-11-30

Completion

2027-12-03

Countries

• South Africa

Study Locations